Johnson & Johnson Press Releases

June 3, 2025

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimen shows 95 percent progression-free survival at four years in transplant-eligible, newly diagnosed patients with multiple myeloma who achieved sustained MRD negativity

More than half of patients maintained minimal residual disease (MRD) negativity (10-5) with DARZALEX FASPRO® for 24 months or longer in the Phase 3 PERSEUS study Data from Phase 3 CEPHEUS study show 60 percent overall MRD negativity (10−5) and improved PFS with DARZALEX FASPRO® in transplant-ineligible newly diagnosed patients

June 3, 2025

Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myeloma

New long-term CARTITUDE-1 data show one-third of patients treated with CARVYKTI® remain progression-free CARTITUDE-4 analysis shows compelling overall survival and progression-free benefits in standard and high-risk subgroups across prior lines of treatment

June 3, 2025

Early results from Johnson & Johnson’s trispecific antibody show promising response in heavily pretreated multiple myeloma patients

Phase 1 trial demonstrates encouraging clinical activity of investigational immunotherapy for relapsed or refractory multiple myeloma Novel investigational dual-antigen-targeting immunotherapy binds to B-cell maturation antigen (BCMA) and GPRC5D on myeloma cells, as well as CD3 on T-cells

June 3, 2025

Johnson & Johnson Launches KINCISE™ 2 System, the Only Automated Surgical Impactor Approved for Knee and Hip Revision Procedures

Next-generation system delivers control1,2,3 while expanding surgical applications4* across primary and revision hip and knee procedures. Now with Acetabular Cup Extraction3,5 the KINCISE™ 2 Surgical Automated System brings added capabilities to complex hip revisions, helping reduce surgeon fatigue6† and streamline surgical workflow5 compared to a traditional mallet.1,2,3

June 3, 2025

Johnson & Johnson leads with first PARP inhibitor combo to improve efficacy in patients with HRR-altered mCSPC

Results from the Phase 3 AMPLITUDE study show the potential of AKEEGA® (niraparib and abiraterone acetate dual-action tablet) to delay cancer progression and worsening of symptoms Data show a nearly 50 percent reduction in disease progression in BRCA-altered mCSPC vs. current standard of care

June 1, 2025

Johnson & Johnson unveils first-in-human results for pasritamig, showing early anti-tumor activity in prostate cancer

Pasritamig, a first-in-class bispecific T-cell-engaging antibody, shows potential in mCRPC with outpatient dosing designed for the community setting Data show low rates of treatment-related adverse events, signaling human kallikrein 2 (KLK2) as a novel, highly specific target

May 28, 2025

Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

May 28, 2025

Johnson & Johnson MedTech Announces New Clinical Data for the MONARCHTM Platform for Robotically-Assisted Bronchoscopy

Largest multi-center prospective robotically-assisted bronchoscopy (RAB) study to date contributes to cannon of scientific evidence and advances clinical understanding

May 22, 2025

Johnson & Johnson showcases latest advancements in cancer innovation with more than 70 clinical and real-world studies at ASCO and EHA

New CARVYKTI® data help shift the treatment paradigm in relapsed or refractory multiple myeloma with five-year progression-free survival rates Late-breaking AKEEGA® data selected for ASCO Press Program, showcasing prostate cancer leadership and potential in patients with HRR-altered mCSPC Early results from next-generation molecules for leukemia, lymphoma, multiple myeloma and prostate cancer showcase pipeline strength

May 21, 2025

Johnson & Johnson to Participate in the Bernstein’s 41st Annual Strategic Decisions Conference

Search Results

No Results

Recently Viewed

Press releases

Press Releases